Greetings from Fire Island. Family function/ disfunction... wife big fight with brother-- topic best left unsaid.
Next weeks stocks-?
Chewie? // XAIR
Next weeks stocks-?
Chewie? // XAIR
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
Intellia Therapeutics price target raised to $130 from $85 at Chardan 16:57 NTLA Chardan analyst Geulah Livshits raised the firm's price target on Intellia Therapeutics to $130 from $85 and keeps a Buy rating on the shares. The company reported initial data from the first Phase I trial of a systemic Crisper therapy, NTLA-2001 in transthyretin amyloidosis, demonstrating a "clean" safety profile and a mean reduction in the circulating misfolded transthyretin biomarker of 87% after a one-time dosing, Livshits tells investors in a research note. If durability holds up and no longer-term safety signals emerge, NTLA-2001 "has the potential to be a functional cure for ATTR," says the analyst. Livshits adds that the results "handily exceed" his base-case expectations for an initial readout, which "now positions NTLA-2001 as a credible contender" in the transthyretin amyloidosis space. Show Related Items >>
I thought that was a joke. I guess not.
https://www.chardan.com/Geulah-Livshits
I say we listen to whatever she has to say Stoney.
You know she's been teased all her life for that name.
I bet she's the smartest biotech analyst out there.
Two thumbs-up.
What are her other picks?
I want an obscure one.
___________________________
Prior to joining Chardan, Dr. Livshits was a Postdoctoral Research Fellow in the laboratory of Dr. Scott Lowe at Memorial Sloan Kettering Cancer Center, where she developed CRISPR and RNAi approaches to study pancreatic cancer in vivo and in organoid models. Dr. Livshits conducted her thesis research in the laboratory of Dr. Elaine Fuchs at The Rockefeller University, where she studied mechanisms of skin development and regeneration. Her doctoral and postdoctoral work has been published in peer-reviewed academic journals including Nature, Nature Medicine, Nature Biotechnology, eLife, PNAS, and Human Gene Therapy.
Dr. Livshits received her BS from Brandeis University, her PhD from The Rockefeller University, and was a Postdoctoral Research Fellow at Memorial Sloan Kettering Cancer Center.
“These are the first ever clinical data suggesting that we can precisely edit target cells within the body to treat genetic disease with a single intravenous infusion of CRISPR. The interim results support our belief that NTLA-2001 has the potential to halt and reverse the devastating complications of ATTR amyloidosis with a single dose,” said Intellia President and Chief Executive Officer John Leonard, M.D. “Solving the challenge of targeted delivery of CRISPR/Cas9 to the liver, as we have with NTLA-2001, also unlocks the door to treating a wide array of other genetic diseases with our modular platform, and we intend to move quickly to advance and expand our pipeline. With these data, we believe we are truly opening a new era of medicine.”
Chewy, Inc. (CHWY) added by ferry to mainland and then pony express... 90% sure we are in at $81 something.....
NYSE - Nasdaq Real Time Price. Currency in USD
82.81+2.46 (+3.06%)<--------------
As of 12:13PM EDT. Market open.
NYSE - Nasdaq Real Time Price. Currency in USD
82.81+2.46 (+3.06%)<--------------
As of 12:13PM EDT. Market open.
I don't even want to tell you I got tipped about NTLA Friday. I just didn't want to take on risk before the beach. Mistake.
What else going on???
Friday wage component<------ WATCH 4% = Correction. Must stay under 4%.
What else going on???
Friday wage component<------ WATCH 4% = Correction. Must stay under 4%.
I don't know why you hate PLTR so much. I told you it would be a steady climber. It's over $27 now.
Just like I said, slow and steady after all the dust settled.
I sold that PLTR at a gain! That's enough for me.
CEL-SCI announces 9.5 year data indicating OS benefit in Multikine patient group 09:27 CVM CEL-SCI announced results…
I used to own this company eons ago at 50 cents!!! CVM
CEL-SCI announces 9.5 year data indicating OS benefit in Multikine patient group 09:27 CVM CEL-SCI announced results…
I used to own this company eons ago at 50 cents!!! CVM